Regulatory Viridian wins FDA approval for Lumvoa for thyroid eye disease PharmaTimesCompany secures first commercial product with data for active and chronic TEDOphthalmologyRead full story pharminent June 29, 2026 (Last updated: June 30, 2026) PharmaTimes Company secures first commercial product with data for active and chronic TED Ophthalmology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Ipsen charts $1.75bn course for Kartos acquisitionNext: Biogen trims Apellis pipeline and R&D team after $5.6bn takeover Related Stories Regulatory Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe pharminent June 29, 2026 Regulatory Replimune gets early August decision date for twice-rejected melanoma drug pharminent June 26, 2026 Regulatory Ionis secures market expansion for Tryngolza as FDA clears severe hypertriglyceridemia use pharminent June 25, 2026
